These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 14610521)

  • 41. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.
    Correia CT; Almeida JP; Santos PE; Sequeira AF; Marques CE; Miguel TS; Abreu RL; Oliveira GG; Vicente AM
    Pharmacogenomics J; 2010 Oct; 10(5):418-30. PubMed ID: 19997080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
    Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
    Aklillu E; Kalow W; Endrenyi L; Harper P; Miura J; Ozdemir V
    Pharmacogenet Genomics; 2007 Nov; 17(11):989-93. PubMed ID: 18075468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders.
    Cusin C; Serretti A; Lattuada E; Lilli R; Lorenzi C; Smeraldi E
    Am J Med Genet; 2002 May; 114(4):380-90. PubMed ID: 11992560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia.
    Illi A; Kampman O; Hänninen K; Anttila S; Mattila KM; Katila H; Rontu R; Hurme M; Lehtimäki T; Leinonen E
    Hum Psychopharmacol; 2007 Jun; 22(4):211-5. PubMed ID: 17526059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.
    Ikeda M; Yamanouchi Y; Kinoshita Y; Kitajima T; Yoshimura R; Hashimoto S; O'Donovan MC; Nakamura J; Ozaki N; Iwata N
    Pharmacogenomics; 2008 Oct; 9(10):1437-43. PubMed ID: 18855532
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.
    Lane HY; Chang YC; Chiu CC; Chen ML; Hsieh MH; Chang WH
    Am J Psychiatry; 2002 Sep; 159(9):1593-5. PubMed ID: 12202283
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC; Lung FW; Chong MY
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response.
    Zhang ZJ; Yao ZJ; Zhang XB; Chen JF; Sun J; Yao H; Hou G; Zhang XB
    Acta Pharmacol Sin; 2003 Mar; 24(3):235-40. PubMed ID: 12617772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A DRD2 polymorphism predicts PANSS score variability in schizophrenia patients treated with antipsychotics.
    Voisey J; Swagell CD; Hughes IP; Barnes M; Burton SC; van Daal A; Morris CP; Lawford BR; Young RM
    Psychiatry Res; 2010 May; 177(3):367-8. PubMed ID: 20388573
    [No Abstract]   [Full Text] [Related]  

  • 53. Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
    Zhang JP; Robinson DG; Gallego JA; John M; Yu J; Addington J; Tohen M; Kane JM; Malhotra AK; Lencz T
    Schizophr Bull; 2015 Nov; 41(6):1248-55. PubMed ID: 26320194
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
    Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
    Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.
    Chen SF; Shen YC; Chen CH
    Psychopharmacology (Berl); 2009 Aug; 205(2):285-92. PubMed ID: 19387614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia.
    Segman RH; Goltser T; Heresco-Levy U; Finkel B; Shalem R; Schlafman M; Yakir A; Greenberg D; Strous R; Lerner A; Shelevoy A; Lerer B
    Pharmacogenomics J; 2003; 3(5):277-83. PubMed ID: 14583797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.
    Lencz T; Robinson DG; Xu K; Ekholm J; Sevy S; Gunduz-Bruce H; Woerner MG; Kane JM; Goldman D; Malhotra AK
    Am J Psychiatry; 2006 Mar; 163(3):529-31. PubMed ID: 16513877
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.
    Xing Q; Qian X; Li H; Wong S; Wu S; Feng G; Duan S; Xu M; Gao R; Qin W; Gao J; Meng J; He L
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):631-7. PubMed ID: 17105675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis.
    Vázquez-Bourgon J; Arranz MJ; Mata I; Pelayo-Terán JM; Pérez-Iglesias R; Medina-González L; Carrasco-Marín E; Vázquez-Barquero JL; Crespo-Facorro B
    Psychiatry Res; 2010 Feb; 175(3):189-94. PubMed ID: 20031235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients.
    Kondo T; Mihara K; Suzuki A; Yasui-Furukori N; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):921-6. PubMed ID: 14499308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.